| Schedule of anticipated integration costs related to the acquired company |
| |
|
Three Months
Ended June 30, 2022 |
|
| |
|
PASITHEA
THERAPEUTICS
CORP. |
|
|
ALPHA 5
INTEGRIN, LLC |
|
|
PRO FROMA
PASITHEA
THERAPEUTICS
CORP. |
|
| |
|
|
|
|
|
|
|
|
|
| Revenues |
|
$ |
13,581 |
|
|
$ |
- |
|
|
$ |
13,581 |
|
| Cost of services |
|
|
15,101 |
|
|
|
- |
|
|
|
15,101 |
|
| Gross margin |
|
|
(1,520 |
) |
|
|
- |
|
|
|
(1,520 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
| Selling, general and administrative |
|
|
3,078,574 |
|
|
|
432,832 |
|
|
|
3,511,406 |
|
| Loss from operations |
|
|
(3,080,094 |
) |
|
|
(432,832 |
) |
|
|
(3,512,926 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Other income: |
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant liabilities |
|
|
421,700 |
|
|
|
- |
|
|
|
421,700 |
|
| Foreign currency exchange gain/(loss) |
|
|
- |
|
|
|
(173 |
) |
|
|
(173 |
) |
| Gain on forgiveness of accounts payable |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Other income |
|
|
421,700 |
|
|
|
(173 |
) |
|
|
421,527 |
|
| Loss before income taxes |
|
|
(2,658,394 |
) |
|
|
(432,659 |
) |
|
|
(3,091,053 |
) |
| Provision for income taxes |
|
|
- |
|
|
|
- |
|
|
|
|
|
| Net loss |
|
$ |
(2,658,394 |
) |
|
$ |
(432,659 |
) |
|
$ |
(3,091,053 |
) |
| Weighted-average common shares outstanding,
basic and diluted |
|
|
|
|
|
|
|
|
|
|
23,373,347 |
|
| Basic and diluted net loss per common
share |
|
|
|
|
|
|
|
|
|
$ |
(0.13 |
) |
| |
|
Six
Months Ended June 30, 2022 |
|
| |
|
PASITHEA
THERAPEUTICS
CORP. |
|
|
ALPHA
5
INTEGRIN, LLC |
|
|
PRO
FROMA
PASITHEA
THERAPEUTICS
CORP. |
|
| |
|
|
|
|
|
|
|
|
|
| Revenues |
|
$ |
27,239 |
|
|
$ |
- |
|
|
$ |
27,239 |
|
| Cost of services |
|
|
28,038 |
|
|
|
|
|
|
|
28,038 |
|
| Gross margin |
|
|
(799 |
) |
|
|
- |
|
|
|
(799 |
) |
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
| Selling,
general and administrative |
|
|
5,483,832 |
|
|
|
978,223 |
|
|
|
6,462,055 |
|
| Loss from operations |
|
|
(5,484,631 |
) |
|
|
(978,223 |
) |
|
|
(6,462,854 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Other income: |
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of warrant
liabilities |
|
|
1,206,997 |
|
|
|
- |
|
|
|
1,206,997 |
|
| Interest expense |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Interest income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Foreign currency exchange gain/(loss) |
|
|
- |
|
|
|
(4,884 |
) |
|
|
(4,884 |
) |
| Gain
on forgiveness of accounts payable |
|
|
45,000 |
|
|
|
- |
|
|
|
45,000 |
|
| Other income |
|
|
1,251,997 |
|
|
|
(4,884 |
) |
|
|
1,247,113 |
|
| Loss before income taxes |
|
|
(4,232,634 |
) |
|
|
(983,107 |
) |
|
|
(5,215,741 |
) |
| Provision
for income taxes |
|
|
- |
|
|
|
- |
|
|
|
|
|
| Net loss |
|
$ |
(4,232,634 |
) |
|
$ |
(983,107 |
) |
|
$ |
(5,215,741 |
) |
| Weighted-average
common shares outstanding, basic and diluted |
|
|
|
|
|
|
|
|
|
|
23,190,859 |
|
| Basic and
diluted net loss per common share |
|
|
|
|
|
|
|
|
|
$ |
(0.22 |
) |
|